INTRODUCTION
Japanese encephalitis virus (JEV), a mosquito-borne pathogen, is endemic in the Asia-Pacific region that includes the five most populous countries of the world: China, India, Indonesia, Pakistan, and Bangladesh (Endy & Nisalak, 2002; Mackenzie et al., 2004) . In JE-endemic areas, JEV is the leading cause of viral encephalitis, primarily in children under 15 years of age (Solomon, 2006) . Antigenically, JEV is most closely related to several encephalitis-causing human pathogens, such as West Nile virus (WNV), St. Louis encephalitis virus and Murray Valley encephalitis virus (Mackenzie et al., 2002) . Genetically, JEV is also related to other clinically important mosquito-borne viruses, including Zika virus (ZIKV), dengue virus (DENV) and yellow fever virus (YFV) (Calisher & Gould, 2003) . From an epidemiological standpoint, although only less than 1 % of individuals infected with JEV typically develop clinical illness (Monath, 2002) , approximately 50 000-175 000 new JE cases are projected to occur annually in JE-endemic countries (Campbell et al., 2011) . JE is fatal in 20-30 % of cases; among JE survivors, 30-50 % experience significant lifelong neurological complications (Solomon, 2006) . Given the relatively high mortality and high risk for long-term morbidity observed in JE patients, JEV remains a major public health problem that affects over half of the world's population living in JE-endemic areas and a large number of people travelling to these areas (Labeaud et al., 2011; Weaver & Barrett, 2004; Weaver & Reisen, 2010) .
single-stranded, positive-sense RNA genome of about 11 000 nt (Yun et al., 2003a) . The genomic RNA has a cap structure at the 5¢ end but lacks a poly(A) tail at the 3¢ end (Lindenbach et al., 2007) ; it contains a single open reading frame (ORF) flanked by the 5¢ and 3¢ non-coding regions (NCRs) that comprises an array of regulatory RNA elements required for viral genome replication and translation (Brinton & Basu, 2015; Gebhard et al., 2011; Paranjape & Harris, 2010; Song et al., 2008; Yun et al., 2009 ). The ORF is translated into a polyprotein precursor of 3432 aa, which is proteolytically cleaved into at least 10 discrete products (Kim et al., 2015) : three structural proteins (capsid, C; premembrane, prM; and envelope, E) required for the formation of infectious virus particles and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) involved in viral RNA replication, viral particle assembly and evasion of innate immunity (Bollati et al., 2010; Brinton, 2014; Westaway et al., 2003; Yun & Lee, 2006 , 2014 . Also, a derivative of NS1 (NS1¢) is synthesized by an RNA pseudoknot-mediated ribosomal frameshift event that occurs between codons 8 and 9 of NS2A, which adds a 52-aa peptide to the C-terminus of NS1 (Firth & Atkins, 2009; Kim et al., 2015; Melian et al., 2010) . Of the eight nonstructural proteins, NS3 and NS5 are the two well-characterized enzymes that are involved in viral RNA replication . NS3 possesses protease, helicase, nucleoside triphosphatase and RNA triphosphatase activities (Assenberg et al., 2009; Luo et al., 2008) , and NS5 has methyltransferase, guanylyltransferase and RNA-dependent RNA polymerase activities (Lu & Gong, 2013) .
JEV is a vaccine-preventable pathogen, with one or more of the four types of JE vaccine being licensed locally in different countries : (i) the mouse brain-derived killed-inactivated vaccine manufactured using the Nakayama or Beijing-1 strain; (ii) the cell culture-derived killed-inactivated vaccine produced using the Beijing-3 or SA 14 -14-2 strain; (iii) the cell culture-derived live-attenuated vaccine generated using the SA 14 -14-2 strain; and (iv) the live chimeric vaccine developed using the live-attenuated YFV 17D as a vaccine vector, in which the prM and E genes of YFV 17D have been replaced by the cognate genes of JEV SA 14 -14-2. Today, the most commonly used JEV strain in vaccine industry is SA 14 -14-2, an attenuated form of the wild-type parental strain SA 14 isolated from a pool of Culex pipiens mosquito larvae in China in 1954 (Yu, 2010) . Given their clinical importance, multiple laboratories have sequenced the genomic RNAs of both SA 14 and SA 14 -14-2, but the sequencing results differ significantly. Based on these studies, SA 14 -14-2 has a significant number of different mutations, ranging from 47 to 64 nt substitutions, when compared to SA 14 (Aihara et al., 1991; Ni et al., 1994 Ni et al., , 1995 Nitayaphan et al., 1990; Song et al., 2012) . It is still unclear, therefore, what sequence differences between SA 14 and SA 14 -14-2 determine their virulence/attenuation phenotypes.
In the present study, we have performed a direct comparative analysis of the phenotypic properties of the two clinically important isogenic JEV strains SA 14 and SA 14 -14-2, which differ in terms of viral replication, gene expression, neuroinvasiveness and neurovirulence. Also, we have compared the complete nt and deduced aa sequences of the genomic RNAs of these two strains. The results of our study provide new information that will be of use in developing better and safer vaccines for JEV and, potentially other closely related encephalitic flaviviruses.
RESULTS
SA 14 -14-2 shows a slower replication kinetics and smaller plaque phenotype than SA 14 in susceptible BHK-21 cells
To analyse in vitro the virological properties of the wildtype SA 14 strain and its attenuated SA 14 -14-2 strain, we first examined the growth kinetics of these two JEV strains in susceptible BHK-21 cells over a period of 3 days post-infection (dpi) at a multiplicity of infection (m.o.i.) of 1. We found that SA 14 -14-2 grew nearly as efficiently as SA 14 , with minor but reproducible differences in kinetics and maximal virus titre. While SA 14 -14-2 reached its maximum titre of 7.8-10Â10
5 plaque-forming units (p.f.u.) ml À1 at 36-48 h post-infection (hpi), SA 14 achieved its peak titre of 3.2-5.6Â10 5 p.f.u. ml À1 at 24-36 hpi, which is 12 h faster (Fig. 1a) . We then determined the accumulation levels of viral genomic RNA in infected cells by real-time quantitative RT-PCR using a JEV-specific fluorogenic probe for the NS3 protein-coding region during the first 24 h following infection. In agreement with the viral growth kinetics, the genomic RNA of SA 14 -14-2 accumulated at a slightly slower rate than did that of SA 14 , estimated to be <0.5-fold slower up to 18 hpi, but becoming~3-fold slower at 24 hpi (Fig. 1b) . Moreover, we assessed the size of the anti-JEV NS3 antibody-immunoreactive plaques formed under a semisolid overlay medium on BHK-21 cells. Clearly, the slower replication kinetics of SA 14 -14-2 were corroborated by a~25 % reduction in plaque size when compared to that of SA 14 at 5 dpi (Fig. 1c) . SA 14 -14-2 has a genome-wide viral protein expression profile virtually identical to that of SA 14 , except that the NS1¢ protein is expressed only by SA 14
To compare the viral protein expression profiles of SA 14 and SA 14 -14-2 on a virus genome-wide scale, we analysed all the viral gene products and their related species produced in BHK-21 cells at 20 hpi with each virus at an m.o.i. of 1, by employing Western blot analysis using a collection of 16 JEV-specific polyclonal antibodies that cover almost completely the protein-coding region of JEV genomic RNA. Initially, when the total cell lysates of mock-, SA 14 -and SA 14 -14-2-infected cells were probed on a blot with a mouse hyperimmune ascitic fluid prepared against JEV Yun et al., 2009 ), a single highly immunoreactive protein of~58 kDa was found only in SA 14 -infected cells and not in SA 14 -14-2-infected cells; also detected were a large number of weakly, moderately and strongly immunoreactive proteins that were commonly found in both SA 14 -and SA 14 -14-2-infected cells (Fig. 2a) . The inability to detect the~58-kDa protein in SA 14 -14-2-infected cells was not a result of the low amount of cell lysate loaded onto the gel, as shown by Western blotting, with an anti-GAPDH rabbit antiserum used as a loading and transfer control (Fig. 2b) .
Based on the observed molecular weight, the~58-kDa SA 14 -specific protein is thought to be the viral NS1¢ protein, a longer form of NS1 (52 additional aa) that is synthesized by an RNA pseudoknot-mediated ribosomal frameshifting at codons 8-9 of NS2A (Firth & Atkins, 2009; Kim et al., 2015; Melian et al., 2010) . To determine whether the~58-kDa protein is JEV NS1¢ and to further examine the expression profile of other viral proteins individually, we conducted a series of Western blot analyses on the same total cell lysates using each of the aforementioned 15 JEV region-specific polyclonal rabbit antisera that we recently generated to identify all the mature viral proteins and their related species (Kim et al., 2015) . The results of these experiments revealed that the~58-kDa protein was indeed the NS1¢ protein, which was the only difference seen in viral protein expression between SA 14 and SA 14 -14-2. Specifically, Western blotting with two antisera, one recognizing the N-terminal 166 residues shared by NS1 and NS1¢ (a-NS1 N-term ) and the other specific for the Cterminal 43 residues of NS1¢ (a-NS1¢ FS ), showed that both the NS1 and NS1¢ proteins were produced in SA 14 -infected cells, but only NS1 (and almost no NS1¢) was expressed in SA 14 -14-2-infected cells (Fig. 2c, d ). The differential expression of NS1¢ was also confirmed by confocal microscopic examination of BHK-21 cells that had been mock-infected or infected with SA 14 or SA 14 -14-2 at an m.o.i. of 1 for 20 h (Fig. 2e) . Except for NS1¢, no significant differences were observed between the SA 14 -and SA 14 -14-2-infected cells in terms of the expression of all other viral proteins, although the accumulation level of multiple NS3-related cleavage products was notably reduced in the SA 14 -14-2-infected cells (Fig. S1 , available in the online Supplementary Material). SA 14 -14-2 is essentially non-neuroinvasive and non-neurovirulent in weanling ICR mice, whereas SA 14 is highly neuroinvasive and neurovirulent
To evaluate the virulence of SA 14 and SA 14 -14-2 in vivo, we used 21-day-old weanling ICR mice, a well-established small animal model for JEV virulence Song et al., 2012; . We addressed two major viral properties: (i) neuroinvasiveness, defined as the ability of viruses to invade the central nervous system (CNS) from a peripheral site of inoculation; and (ii) neurovirulence, N-term or a-NS1¢ FS rabbit antiserum. Immunoreactive proteins were visualized by incubation with an Alexa 488-conjugated goat anti-rabbit IgG (green). Cell nuclei were counterstained with DAPI (blue). Fluorescent images were taken on a confocal microscope. Representative merged images are shown, with inset images that represent enlarged views of the boxed regions where DAPI staining is excluded.
defined as the ability of viruses to induce neurological disease within the CNS. First, neuroinvasiveness was quantified by creating survival curves and determining the lethal dose 50 % (LD 50 ) values following intramuscular (IM) inoculations. We found that an inoculum of as little as 1.5 p.f.u. of SA 14 caused typical signs of clinical encephalitis (including ruffled fur, tremors, hunched posture and hind limb paralysis) and ultimately death by 7-11 dpi in 8 of 10 infected mice; thus, the estimated IM LD 50 value for SA 14 was <1.5 p.f.u. (Fig. 3a, IM) . In contrast, SA 14 -14-2 inoculation did not produce any clinical signs of disease, even at the highest dose of 1.5Â10 5 p.f.u. per mouse, indicating a reduction of at least five orders of magnitude in the ability to invade the CNS (Fig. 3b, IM) . In all dead mice, the accumulation of viral genomic RNA in brain tissues was confirmed by real-time quantitative RT-PCR(data not shown).
Next, neurovirulence was quantified by generating the survival curves and measuring the LD 50 values following intracerebral (IC) inoculation. We noted that all the SA 14 -infected mice, regardless of the dose of inoculum, displayed clinical signs of JEV infection and died rapidly, with even the lowest dose of 1.5 p.f.u. per mouse resulting in 100 % mortality by 4-8 dpi; therefore, the IC LD 50 value for SA 14 was estimated to be <1.5 p.f.u. (Fig. 3a, IC) . On the other hand, SA 14 -14-2 lost the ability to induce fatal encephalitis within the CNS, having an IC LD 50 value of >1.5Â10 5 p.f.u., at least five orders of magnitude higher than that of SA 14 (Fig. 3b, IC) . More specifically, only 1 or 3 of 10 mice infected intracerebrally with the two highest doses of SA 14 -14-2 (i.e. 1.5Â10 4 or 1.5Â10 5 p.f.u. per mouse, respectively) developed typical symptoms and death by 7-10 dpi, and all the mice infected intracerebrally with relatively low doses (i.e. 1.5 to 1.5Â10 3 p.f. u. per mouse) remained healthy, with no apparent clinical signs (Fig. 3b, IC) . In all the dead mice, viral replication in the brain tissue was verified by virus titration via plaque assays on BHK-21 cells after the 24-day experiments (data not shown). Moreover, total RNA was extracted from the brain homogenates of the four mice that died after an IC inoculation of SA 14 -14-2. The sequence analysis of cDNA generated by reverse transcription-PCR demonstrated that these viruses all had a G 1708 fiA substitution changing a Gly with Glu at position 244 of the viral E protein (data not shown), which is the single point mutation that has been shown to be sufficient to confer a dramatic increase in neurovirulence in mice . SA 14 -14-2 is non-neurovirulent in ICR mice older than 14 days of age but highly neurovirulent in those younger than 7 days of age As part of the guidelines for the production and quality control of the live JE vaccine SA 14 -14-2, mice have been routinely used to test the attenuation phenotypes of the virus master and/or working seeds (Kimura et al., 2010; Yu, 2010) . In particular, weanling mice are used to determine the level of viral virulence, whereas suckling mice are used to evaluate any potential reversion of the virus to virulence (World Health Organization, 2012 ). This age difference led us to examine the sensitivity to SA 14 -14-2 infection of preweaning mice of different ages following IC inoculation, which is the most sensitive method for detecting JEVs. To this end, groups of ICR mice were inoculated intracerebrally at 1, 3, 7 or 14 days of age with serial 10-fold dilutions of SA 14 -14-2 (ranging from 1.5 to 1.5Â10 3 p.f.u. per mouse) in order to calculate LD 50 values based on the resulting survival curves. The results showed that clinical signs and even death occurred in nearly all neonatal mice inoculated at 1, 3 or 7 days of age, invariably with an LD 50 of <1.5 to 3 p.f.u., but all neonatal mice inoculated at 14 days survived without any symptoms of JE, with an LD 50 of >1.5Â10 3 p.f.u. (Fig. 4) . Although the observed clinical signs were the same, mice of different ages had different survival times. Notably, both 1-and 3-day-old mice showed 100 % mortality at 6-9 dpi and 6-12 dpi, respectively. All 7-day-old mice inoculated with each of the two higher doses succumbed to infection at 7-10 dpi, but 5 of these 12 older mice inoculated with one of the two lower doses survived until the completion of the 24-day experiment. No mortality was observed among the 14-day-old mice, even with the highest dose inoculated. These data indicate that 1-day-old mice are the most sensitive to SA 14 -14-2, and the symptoms and mortality rates decrease as age increases.
To verify the ability of SA 14 -14-2 to replicate in the brains of 1-day-old ICR mice, we examined the expression of the viral NS1 protein by Western blot analysis of whole-brain homogenates prepared at 5.5 dpi from the mice inoculated intracerebrally with the virus at 15 p.f.u. per mouse. As negative and positive controls, the mice were mock-inoculated or inoculated intracerebrally with the same amount of SA 14 in parallel. Western blotting using the antibody pair a-NS1
N-term and a-NS1¢ FS revealed that markedly high levels of both NS1 and NS1¢ proteins were produced in all the brains of the three SA 14 -infected mice that we tested; in comparison, significantly low but detectable levels of NS1 protein, but not NS1¢, were expressed in all three SA 14 -14-2-infected mouse brains (Fig. S2 ). In line with our finding, the lower level of SA 14 -14-2 RNA replication in brain tissue was also confirmed by real-time quantitative RT-PCR using a primer pair specific for the viral NS3 proteincoding region (data not shown). Thus, our results showed that SA 14 -14-2 is capable of actively replicating in the brains of suckling mice, albeit at a significantly slower rate than SA 14 .
The genomes of SA 14 and SA 14 -14-2 differ by 57 nucleotides encoding 25 amino acid substitutions
In our earlier work, we reported the complete genome sequence of the attenuated SA 14 -14-2 virus retrieved from a pool of commercial vaccine vials . To define the genetic changes acquired during the attenuation process, in the present study we determined the complete genome sequence of the pre-attenuated virulent SA 14 virus, employing the same sequencing strategy we used for the SA 14 -14-2 virus. Specifically, the entire viral genomic RNA was converted by reverse transcription-PCR into four overlapping cDNA fragments (data not shown): Frag-1 (nt 1-2553), Frag-2 (nt 1800-5950), Frag-3 (nt 5500-9401) and Frag-4 (nt 9200-10 977). After gel purification, the four cDNA amplicons were directly sequenced to avoid selection bias that might occur during cloning steps. The consensus sequences of the utmost 5¢-and 3¢-terminal regions served as a primer binding site for our reverse transcription-PCR and were analysed by self-ligation of the decapped viral RNA, reverse transcription-PCR amplification of the ligated 3¢-5¢ junction region, cloning of the cDNA amplicons and then sequencing of 22 randomly picked clones with an insert (data not shown). As we documented previously for SA 14 -14-2 , the full-length genome of SA 14 was also 10 977 nt long, comprising a 95-nt 5¢NCR, a 10 299-nt ORF and a 583-nt 3¢NCR. Thus, our genomic sequences of SA 14 and SA 14 -14-2 were always one nt longer than all the previously reported genomic sequences of these two strains, due to the insertion of a single guanine at nt position 10 701 in the 3¢NCR.
We then compared the complete nt and deduced aa sequences of the genomic RNAs between the SA 14 (GenBank accession no. KU323483) and SA 14 -14-2 (accession no. JN604986) viruses that we sequenced in our present and previous studies, respectively. As summarized in Table 1 , we found a total of 57 nt changes, corresponding to 25 aa substitutions, distributed across the entire viral genome. In addition to our own studies, there are other multiple but not identical whole-genome sequences currently available from the GenBank sequence database for both SA 14 (accession nos. U14163, D90194 and M55506) and SA 14 -14-2 (accession nos. D90195 and AF315119), and they differ by 47-64 nt causing 17-27 missense mutations. In order to define the nt and aa residues that consistently differ between SA 14 and SA 14 -14-2, we performed comparative sequence analyses using all seven currently available viral genome sequences. Of the 57 nt (25 aa) differences we identified in this study, a panel of 38 nt (15 aa) were invariably different between the consensus genome sequences of SA 14 and SA 14 -14-2 (Table 1 , open circles): 1 in 5¢NCR, 1 in C, 7 in E, 1 in NS1, 3 in NS2A, 2 in NS2B, 5 in NS3, 1 in NS4A, 4 in NS4B, 12 in NS5 and 1 in 3¢NCR. Thus, the presence of these consistent nt or aa changes implies a strong association between at least a subset of these genetic changes and the attenuated phenotype. SA 14 -14-2 contains a single silent G 3599 fiA substitution within the predicted RNA pseudoknot involved in promoting a À1 ribosomal frameshift for the synthesis of NS1¢
In susceptible BHK-21 cells, the viral protein expression profile produced by SA 14 was identical to that generated by SA 14 -14-2, except that the NS1¢ protein was synthesized exclusively by SA 14 , and not by SA 14 -14-2 (Figs 2 and S1). Given the fact that NS1¢ is a À1 frameshifted product of the NS1 protein expressed by JEV and other JE serogroup viruses (Firth & Atkins, 2009; Kim et al., 2015; Melian et al., 2010) , we compared the nt sequences of the genomes of SA 14 and SA 14 -14-2 in the 80 nt core region (nt 3551-3630) that contains two putative stimulatory elements for the ribosomal frameshifting ( ) and (ii) a potential RNA pseudoknot starting 6 nt downstream of the slippery sequence. In the case of SA 14 , the predicted pseudoknot consists of two directly adjacent, presumably coaxially stacked stem loops (SL1 and SL2) with a 5 nt loop region ( 3585 CUGGC 3589 ) of SL1 base-paired with its complementary sequence ( 3621 GCCAG 3625 ), 6 nt downstream of SL2 (Fig. 5a ). Comparison to SA 14 showed that SA 14 -14-2 retained the same heptanucleotide but acquired a single silent G-to-A substitution at nt position 3599 (Table 1) ; this G 3599 A transition mutation converts the C 3570 -G 3599 base pair to a C 3570 -A 3599 mismatch pair near the base of the stem of SL1, thereby destabilizing the integrity of SL1 and thus disrupting the overall arrangement of the heptanucleotide and predicted pseudoknot (Fig. 5b) . In agreement with our results, a recent short report has indicated that the introduction of the single point mutation G
3599
A is capable of abolishing the expression of SA 14 NS1¢ (Ye et al., 2012) .
Both the heptanucleotide slippery sequence and predicted RNA pseudoknot are highly conserved among all fully sequenced JEV isolates
To assess the conservation status of the heptanucleotide slippery sequence and predicted RNA pseudoknot, we performed a multiple sequence alignment using the nt sequences of the core frameshift-promoting region (nt 3551-3630) of all 154 full-length JEV genomes retrievable from the GenBank sequence database. In this analysis, we included all four different versions of SA 14 , three different versions of SA 14 -14-2 and one of each of two other SA 14 -derived attenuated strains (i.e. SA 14 -2-8 and SA 14 -12-1-7). As summarized in Fig. 6 , 128 of the 154 JEV genomes have the same 
nt sequence that is also found in the first three versions of SA 14 (accession nos. KU323483, U14163 and D90194), but the last one (accession no. M55506) has the single G-to-A substitution at nt position 3599 that is identified in all three SA 14 -derived attenuated strains (SA 14 -2-8, SA 14 -12-1-7 and all three versions of SA 14 -14-2). Thus, the presence of the G
A substitution in the SA 14 genomic sequence deposited under accession no. M55506 is presumably a result of variations in the cultivation history of the virus. Of particular interest is the fact that the same G 3599 A substitution also appears in the genome of GD/01 (accession no. KF297915), a JEV strain isolated from an aborted pig foetus in China in 2009. Moreover, of the three SA 14 -derived attenuated strains that have the common G 3599 A substitution acquired during attenuation process, SA 14 -2-8 has one additional nt substitution (U 3584 C) located in the loop of SL1, but not involved in the predicted pseudoknot base-pairing (Fig. S3) . This U 3584 C substitution is also noted in the genome of Nakayama (accession no. EF571853), the first JEV isolate recovered from a JE patient in Japan in 1935, after one passage in Vero cells. DISCUSSION SA 14 -14-2 is a JE vaccine strain derived from its parent SA 14 by the acquisition of spontaneous mutations after an intricate course of~150 serial passages in hosts, switching between cultured cells (primary hamster kidney and primary chick embryo cells) and non-neural tissues/organs of live animals (mice and hamsters) to minimize its viral pathogenicity and maximize immunogenicity (Yu, 2010) . In recent years, SA 14 -14-2 has become the most widely used JEV strain in the production of cell culture-based live-attenuated and killedinactivated JE vaccines (Halstead & Thomas, 2011; WilderSmith & Halstead, 2010; . Because of their clinical importance, each genomic RNA of both the SA 14 and SA 14 -14-2 strains has already been independently sequenced in full by several research groups, but their results have differed significantly. According to these earlier studies, SA 14 -14-2 has been reported to have a large number of different point mutations, i.e. 47-64 single-nucleotide changes causing 17-27 aa substitutions, as compared to SA 14 (Aihara et al., 1991; Ni et al., 1994 Ni et al., , 1995 Nitayaphan et al., 1990; Song et al., 2012) . The discrepancy in the number and identity of these mutations is primarily a result of the different passage 
○ *Nucleotide and amino acid changes are shown by the standard one-letter code.
-, Silent mutation.
histories of the virus preparations used for sequencing . Therefore, these prior reports indicate that the need exists to gain a clearer understanding of the genetic changes occurring during the attenuation of JEV SA 14 , so that the viral genetic factors involved in virulence can be investigated by targeted site-directed mutagenesis and an efficacious, yet safer, vaccine strain can be developed through selective engineering of the viral virulence factors.
In the current study, we performed a series of comparative experiments (i) to evaluate the in vitro and in vivo virological properties of SA 14 and SA 14 -14-2 in parallel, (ii) to determine their consensus whole genome sequences, (iii) to analyse the genetic variation between these two isogenic but pathogenically distinct strains, and (iv) to differentiate the SA 14 and its derivatives among all 154 publicly available fully sequenced JEV strains. For our study, SA 14 was initially . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  SA14   (M55506)   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  SA14-2-8   (U15763)   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  SA14-12-1-7   (AF416457)   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  SA14-14-2   (JN604986)   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . HN0626 (JN381837)
. . . U . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . BL06-50 (JF706270)
. . . U . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . a One hundred twenty eight complete genome sequences are available in GenBank: AB196923, AB196925, AB196926, AB241118, AB241119, AB551990, AB551991, AB551992, AB594829, AB698906, AB698907, AB698908, AB698909, AB830335, AB853904, AF069076, AF075723, AF098735, AF098737, AF217620, AF221499, AF221500, AF254452, AF254453, AY303791, AY303792, AY303793, AY303794, AY303795, AY303796, AY303797, AY303798, AY316157, AY508812, AY508813, AY585242, AY585243, EF107523, EF543861, EF623987, EF623988, EU429297, EU693899, FJ185036, FJ185037, FJ495189, GQ199609, GQ902060, GQ902061, GQ902062, GQ902063, GU187972, GU205163, GU556217, HM228921, HM366552, HQ893545, JF499788, JF499789, JF499790, JF706267, JF706268, JF706269, JF706271, JF706272, JF706273, JF706275, JF706276, JF706277, JF706278, JF706279, JF706280, JF706281, JF706282, JF706283, JF706284, JF706285, JF706286, JN381830, JN381831, JN381832, JN381833, JN381834, JN381835, JN381836, JN381839, JN381841, JN381842, JN381843, JN381844, JN381845, JN381846, JN381848, JN381849, JN381850, JN381851, JN381852, JN381853, JN381854, JN381855, JN381856, JN381857, JN381858, JN381859, JN381860, JN381861, JN381862, JN381864, JN381865, JN381866, JN381867, JN381868, JN381869, JN381870, JN381871, JN381872, JQ031753, JX072965, KC196115, L78128, NC_001437, U47032, KC915016, JN381873, JX050179, AB698905, EU880214, and EF623989. Multiple sequence alignments were performed using the nt sequence of all 154 currently available fully sequenced JEV genomes, including four different versions of SA 14 , three different versions of SA 14 -14-2 and two other SA 14 -derived attenuated strains (SA 14 -2-8 and SA 14 -12-1-7). The consensus sequence of the 80 nt frameshift-promoting region is shown on top, and only differences from that sequence are presented. As described in Fig. 5 , the sequences corresponding to the heptanucleotide slippery sequence (blue) and involved in the formation of stem-loop 1 (orange), stem-loop 2 (magenta) and pseudoknot basepairing (green) are shown. The silent point mutation G 3599 A is highlighted in red.
obtained from the Biodefense and Emerging Infections (BEI) Resources Repository and amplified once in BHK-21 cells before use, and SA 14 -14-2 was recovered directly from BHK-21 cells after transfection with infectious RNA transcripts derived from its stably cloned full-length cDNA that had been constructed using the virus retrieved from a pool of commercial vaccine vials . In susceptible BHK-21 cells, a side-by-side comparison of this isogenic virus pair revealed that SA 14 -14-2 grew at an only marginally slower rate than SA 14 , and this small difference was corroborated by a slight delay in the accumulation of viral RNA and proteins in infected cells, paralleling the small reduction in plaque size noted previously (Aihara et al., 1991; Yu & Wang, 1986) . Similar differences in viral growth were also observed in two other susceptible cell lines, SH-SY5Y (human neuroblastoma) and C6/36 (mosquito larva), which are frequently used to assess viral replicability with respect to pathogenesis and transmission, respectively (data not shown). Despite their almost equivalent replicability in cell culture, however, SA 14 -14-2 was essentially avirulent, displaying neither neuroinvasiveness nor neurovirulence for weanling ICR mice, a small animal model that faithfully reproduces fatal encephalitis reported in JE patients Song et al., 2012; ; in stark contrast, SA 14 was highly virulent, exhibiting lethal neuroinvasiveness and neurovirulence in the mice. Our mouse infection data are in good agreement with the results of previous in vivo infection studies using mice and other laboratory animals (hamsters, guinea pigs and monkeys) that have been summarized in a recent English review of a handful of earlier Chinese reports (Yu, 2013) .
After defining their phenotypic differences both in vitro and in vivo, we aimed to identify the genetic variation in the attenuated JE vaccine SA 14 -14-2 virus that rendered it avirulent in weanling ICR mice, by conducting a comparative genome analysis against its pre-attenuated virulent SA 14 virus. To do so, we determined the complete genome sequence of SA 14 and compared it with that of its attenuated counterpart SA 14 -14-2, which we had determined in a previous study . We found a total of 57 nt substitutions dispersed virtually all over the genome, 25 of which led to aa changes in 9 of 10 major viral proteins, excluding NS4A. It is of particular note that over one-third (9) of the 25 mis-sense mutations were located in the SA 14 -14-2 E protein (i.e. L R), implying that the mutations in the E protein-coding region contribute to viral attenuation. Very recently, the E protein-mediated virulence attenuation of SA 14 -14-2 has been demonstrated by employing a contemporary single plasmid-based reverse genetics systems in JEV: (i) using an infectious cDNA clone of SA 14 -14-2, a single Gly-to-Glu change at position 244 of the viral E protein alone was shown to be sufficient to confer lethal neurovirulence in weanling ICR mice by promoting viral infectivity into neurons within the CNS, but insufficient to provide any detectable level of neuroinvasiveness . (ii) Using an infectious cDNA clone of a wild-type JEV strain, 7812474, an intertypic virus encoding the entire E protein of SA 14 -14-2 with 10 aa substitutions (L M) appeared to retain substantial levels of neuroinvasiveness and neurovirulence (Gromowski et al., 2015b) . These previous studies, together with our findings described in the current report, indicate that most, if not all, of the nine mutations in the SA 14 -14-2 E protein are necessary for the stable loss of both neuroinvasiveness and neurovirulence in mice.
Prior to our development of the first one plasmid-based reverse genetics system for JEV (Yunet al., 2003b) , SA 14 -14-2 E protein-mediated neurovirulence attenuation was probed in 3-to 4-week-old ICR mice, using a two plasmidbased system to recover the attenuated YFV 17D and its chimeric derivative, in which the prM and E genes of YFV 17D were replaced with those of JEV SA 14 -14-2. In this earlier study, the four mutations (F 107 L, K 138 E, V 176 I and A 177 T) reverted in the SA 14 -14-2 E protein were documented to be the minimal number of mutations needed to restore a neurovirulent phenotype to the chimera YFV/JEV SA 14 -14-2 (Arroyo et al., 2001) . On the other hand, a recent study showed that the four reported E protein mutations (L 107 F, E 138 K, I 176 V, and T 177 A), together with two others (Q 264 H and K 279 M), are unable to completely attenuate the neurovirulence of the wild-type JEV strain 7812474 (Gromowski et al., 2015b) . These two reports thus suggest that virus chimerization by itself may contribute to some extent to the neurovirulence attenuation of the chimera YFV/JEV SA 14 -14-2, which is also in accordance with those data previously reported Guirakhooet al., 1999) . Along this line, the most recent efforts have been directed toward the development of live-attenuated chimeric virus vaccine candidates against WNV, DENV and tick-borne encephalitis virus, by engineering each of their prM and E genes into the genome of the live JE vaccine SA 14 -14-2 virus (Li et al., 2013a, b; Wang et al., 2014) . In order to achieve an adequate level of attenuation using this strategy, it may be necessary to further modify specific virulence-associated aa residues located in the prM and E proteins of the individual chimeric viruses. Therefore, we need to have a clear understanding of the roles of viral prM and E proteins and their specific residues involved in virulence of JEV and related flaviviruses.
Over the past two decades, complete genome sequences for both SA 14 and SA 14 -14-2 have been determined multiple times by four independent research teams in order to define the viral genetic elements responsible for the attenuation of SA 14 -14-2. To date, however, this goal has not been fully achieved because each of the two viral genomic sequences deposited in GenBank varies considerably in its different versions, mainly as the result of differences in virus cultivation histories, resulting in an estimated number of 47-64 nt differences and 17-27 aa alterations between SA 14 and SA 14 -14-2 (Aihara et al., 1991; Ni et al., 1994 Ni et al., , 1995 Nitayaphan et al., 1990; Song et al., 2012) . Consequently, this discrepancy in the number and identity of the mutations makes it difficult to directly compare the results of previous genetic studies, each obtained using a different version of the viral sequence of SA 14 -14-2 or SA 14 (Arroyo et al., 2001; Chambers et al., 2007 Chambers et al., , 1999 Eckels et al., 1988; Gromowski et al., 2015a, b; Guirakhoo et al., 1999; Yang et al., 2014; . In the present study, we therefore determined the differences between our genome sequences for SA 14 and SA 14 -14-2 and then compared them with all their previously reported sequences, in order to identify the genetic changes that differ consistently between the two viruses. Of the 57 nt (25 aa) substitutions that we found in the current study, 38 nt (15 aa) substitutions were shown to be present in every case in the genome of SA 14 -14-2, when compared to that of SA 14 , regardless of the version of the viral genome sequences used. These findings are similar to those previously reported (Gromowski et al., 2015b) . On one hand, these consistent nt and aa changes clearly represent primary targets for future genetic studies aimed at understanding the molecular basis for virulence of the wild-type strain SA 14 and, conversely, for the attenuation of its isogenic vaccine strain SA 14 -14-2. On the other hand, we should also consider other less consistent mutations observed in only a subset of the different currently available versions of the genomic sequence of SA 14 -14-2 (three versions) or SA 14 (four versions). One good example is the single silent G-to-A substitution at position 3599 of the SA 14 -14-2 genome, which has been reported to be sufficient to ablate the expression of NS1¢ and contribute to viral attenuation (Ye et al., 2012) . At this locus, three of the four versions of the SA 14 genome sequence have the wild-type guanine, while the remaining version possesses the mutated adenine that is detected in all three versions of the SA 14 -14-2 genome sequence. Clearly, further investigations are warranted to determine the collection of mutations responsible for the attenuation of SA 14 -14-2 and the multigenic nature of its attenuation.
Recently, we profiled a comprehensive landscape of the viral proteins expressed from the genomic RNA of the virulent JEV strain CNU/LP2, using a panel of 15 JEV-specific polyclonal rabbit antisera that cover all parts of the viral proteincoding regions (Kim et al., 2015) . Using the same antisera, we have now compared the expression profiles of all viral proteins detectable in BHK-21 cells infected with SA 14 and SA 14 -14-2 individually. We found that the viral protein expression profile of SA 14 was essentially identical to that of CNU/LP2, corroborating our previous report (Kim et al., 2015) . More importantly, our results showed no significant difference in the viral protein expression profiles of SA 14 and SA 14 -14-2, except that the NS1¢ protein was expressed in SA 14 -infected cells but not in SA 14 -14-2-infected cells to any detectable level. Initially, a bioinformatics-based study proposed that the NS1¢ protein is the product of an RNA pseudoknot-mediated ribosomal frameshift (Firth & Atkins, 2009 ). Subsequently, the proposed frameshifting was experimentally established for the NS1¢ proteins of JEV and WNV, and its role in virulence was tested in mice (Kim et al., 2015; Melian et al., 2010; Ye et al., 2012) . We found only a single silent point mutation, G 3599 A, within the 80 nt frameshiftpromoting region in our genomic sequence of SA 14 -14-2 (accession no. JN604986), relative to that of SA 14 (accession no. KU323483). This result is consistent with a recent report demonstrating that the G 3599 A substitution alone is sufficient to abolish the synthesis of SA 14 NS1¢ (Ye et al., 2012) . Also, our sequence alignment using all 154 available fulllength JEV genomes revealed that the G 3599 A substitution is present in the genomes of all three SA 14 -derived attenuated strains (SA 14 -2-8, SA 14 -12-1-7 and SA 14 -14-2) as well as the Chinese GD/01 strain isolated from an aborted pig foetus in 2009. Interestingly, the GD/01 strain is closely related to the SA 14 -14-2 strain, with 99.7 % identity at the nt level and 99.6 % identity at the aa level (Liu et al., 2013) . This strong similarity raises the possibility that the live JE vaccine SA 14 -14-2 virus may have been released into the environment. In addition to the G 3599 A substitution, 18 additional point mutations were also found within the frameshift-promoting region in 21 of the 154 JEV genomes. Of these 18 mutations, two (G 3600 A and C 3606 G) are predicted to alter the pseudoknot formation. Further studies are needed to define the precise genetic elements required for the NS1¢ frameshifting and its role in viral replication and pathogenesis.
In summary, SA 14 -14-2 is a highly attenuated form of the fully virulent wild-type JEV strain SA 14 . About 25 years ago, SA 14 -14-2 was used to develop the cell culture-derived, liveattenuated JE vaccine marketed as SA14-14-2 in China (Yu, 2013) . Since then, this live vaccine has been administered to >300 million children in China and progressively licensed for use in other Asian countries (South Korea, Nepal, India, Sri Lanka, Cambodia, Laos, Myanmar and Thailand) , with an outstanding profile of efficacy and safety . In the present report, we have described a constellation of differential phenotypic and genotypic traits between the SA 14 -14-2 strain and its pre-attenuated parent SA 14 strain. It is of particular significance that we have identified a total of 57 single-nucleotide substitutions and 25 aa changes accumulated within the genomic RNA of SA 14 -14-2, when compared to that of SA 14 , with their in vitro and in vivo phenotypes being substantiated. Now, the isogenic virus pair SA 14 and SA 14 -14-2 provides a solid grounding and a unique opportunity to study the genetic variation that is associated with the virulent properties of SA 14 and, conversely, the attenuated properties of SA 14 -14-2. Further investigation is warranted using targeted site-directed mutagenesis to determine viral virulence factors for JEV and their underlying mechanisms. The results of these investigations may afford an exciting new direction in the prevention and treatment of life-threatening infections with JEV and possibly other taxonomically related flaviviruses, particularly several clinically important human pathogens (e.g. ZIKV, WNV and DENV).
METHODS
Cells and viruses. Baby hamster kidney (BHK-21) cells were maintained as previously described (Yun et al., 2003b) . A vial of JEV SA 14 was originally obtained from the National Institutes of Health-supported BEI Resources Repository (catalogue no. NR-2335) and propagated once in BHK-21 cells prior to use in this study. A stock of JEV SA 14 -14-2 was generated in BHK-21 cells by transfecting the RNA transcripts synthesized in vitro from its full-length infectious cDNA clone , which had been constructed using the virus retrieved from a batch of the commercial JE vaccine SA14-14-2 vials .
Plaque size determination. Naïve BHK-21 cells were pre-seeded overnight in 6-well plates (3Â10 5 cells per well). Cells were mockinfected or infected with serial 10-fold dilutions of JEV SA 14 or SA 14 -14-2 at 37 C for 1 h with frequent agitation. After incubation, the virus inoculum was removed from the cells and the cell monolayers were overlaid with 3 ml of alpha minimal essential medium (MEM) containing 10 % FBS and 0.5 % SeaKem LE Agarose (FMC BioProducts). Five days after infection, viral plaques were visualized by immunostaining as described previously (Yun et al., 2009) . In brief, the cells were fixed with 7 % formaldehyde, permeabilized with 0.25 % Triton X-100 and stained with an anti-JEV NS3 rabbit antiserum [a-NS3 C-term , diluted 1 : 1000 (Kim et al., 2015) ] followed by a horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (diluted 1 : 1000; Jackson ImmunoResearch). The plaques were developed by incubation with 3,3¢-diaminobenzidine (DAB, Vector).
Real-time quantitative RT-PCR. Total intracellular RNAs were extracted with Trizol reagent (Invitrogen). TaqMan assays were used to quantify the JEV genomic RNA, and the cellular b-actin mRNA was used as an internal standard. The nt sequences of the primer pairs and fluorogenic probes are listed in Table 2 : the SAprimerF+SAprimerR and SAprobe specific for the JEV NS3 protein-coding region and the BHKprimerF+BHKprimerR and BHKprobe specific for the BHK-21 bactin-coding region. Complementary DNAs were synthesized at 50 C for 30 min with Superscript III reverse transcriptase (Invitrogen), followed by inactivation of the reverse transcriptase at 70 C for 15 min. The cDNAs were then amplified with the iQ Supermix quantitative PCR system (Bio-Rad) and detected with the iCycler iQ multicolour realtime PCR detection system (Bio-Rad). The thermal cycling conditions were as follows: 3 min at 95 C, followed by 45 cycles of 15 s at 95 C and 1 min at 60 C. The relative quantifications were analysed using the 2 ÀDDCt method (Schmittgen et al., 2000; Winer et al., 1999) . The results included in this assay are the averages of two independent experiments analysed twice by quantitative RT-PCR.
Western blot analysis. Cells were lysed in sample buffer [80 mM Tris-HCl (pH 6.8), 2.0 % SDS, 10 % glycerol, 0.1 M dithiothreitol and 0.2 % bromophenol blue]. The same amounts of cell lysates were heatdenatured and separated by SDS-PAGE. Separated proteins were transferred to a methanol-activated polyvinylidene difluoride membrane (Bio-Rad) and blocked in PBS containing 0.2 % Tween 20 and 5 % nonfat milk. Membranes were probed with a JEV-specific mouse hyperimmune antiserum [a-JEV, diluted 1 : 1000 (Yun et al., 2003b) ] or a polyclonal rabbit antiserum specific for JEV NS1 [a-NS1 N-term , diluted 1 : 3000 (Kim et al., 2015) ], JEV NS1¢ [a-NS1¢ FS , diluted 1 : 1000 (Kim et al., 2015) ] or GAPDH (a-GAPDH, diluted 1 : 5000; VWR). The antigen-primary antibody complexes were recognized by an alkaline phosphatase (AP)-conjugated goat anti-mouse or anti-rabbit IgG (diluted 1 : 5000; Jackson ImmunoResearch), as appropriate. Antibody binding was visualized using the colorimetric detection of AP activity with 5- *JEV-specific sequences are indicated in uppercase letters. BHK-21 b-actin-specific sequences are shown in lowercase italic letters. †Nucleotide position refers to the complete genome sequence of JEV SA 14 -14-2 (GenBank accession no. JN604986) or to the mRNA sequence of BHK-21 b-actin (GenBank accession no. AJ312092).
bromo-4-chloro-3-indolyl phosphate (BCIP) and nitro blue tetrazolium (NBT) as substrates.
Immunofluorescence analysis. Cells were fixed and permeabilized in ice-cold methanol at À20 C for 10 min. They were washed three times for 10 min each in PBS and incubated in PBS with 5 % BSA for 30 min at room temperature. The cells were then washed three times for 10 min each in PBS and incubated at room temperature for 1 h with a rabbit antiserum specific for JEV NS1 [a-NS1 N-term , diluted 1 : 2000 (Kim et al., 2015) ] or NS1¢ [a-NS1¢ FS , diluted 1 : 2000 (Kim et al., 2015) ] in PBS with 2.5 % BSA. After incubation, they were washed three times for 10 min each in PBS and incubated at room temperature for 1 h with an Alexa 488-conjugated goat anti-rabbit IgG (diluted 1 : 1000; Molecular Probes) in PBS with 2.5 % BSA. Subsequently, they were washed three times for 10 min each in PBS and stained with 300 nM DAPI (Molecular Probes) in PBS at room temperature for 5 min. Finally, they were washed three times for 10 min each in PBS and mounted in a fluorescence mounting medium (Dako). Stained cells were analysed under an LSM-710 confocal microscope equipped with the Zen 2010 software (Carl Zeiss).
Animal studies. Viral virulence was examined in a mouse model of JEV infection, as we described previously . All mice were purchased from Charles River. Three-week-old weanling female ICR (CD-1) mice were used to measure viral neuroinvasiveness and neurovirulence, and younger mice (1, 3, 7 and 14 days of age) were used to examine age-dependent susceptibility to virus infection. The mice were inoculated intramuscularly with 50 µl or intracerebrally with 20 µl of serial 10-fold dilutions of JEV SA 14 or SA 14 -14-2 in MEM. After infection, the mice were observed twice a day for 24 days to monitor any JEV-induced clinical symptoms or death, or euthanized for animal welfare reasons when severe clinical signs had developed. The LD 50 value for each virus was calculated by the Reed-Muench method (Reed & Muench, 1938) , and the survival curve was created by the Kaplan-Meier method (Kaplan & Meier, 1958) .
Ethics statement. All animal studies were conducted within the Animal Biosafety Level 3+ facility located in the USTAR Bioinnovations Center in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Utah State University (IACUC approval number 2505). Discomfort, distress, pain and injury were minimized as much as possible through limited handling and euthanization of mice when they were moribund.
Viral genome sequencing. JEV genomic RNA was isolated from the culture supernatant of JEV-infected BHK-21 cells with TRIzol LS Reagent (Invitrogen). The extracted RNA was used to synthesize four overlapping cDNA fragments (Frag-1 to Frag-4) that represent the fulllength viral genome, except for the 5¢ and 3¢ ends; Superscript III reverse transcriptase (Invitrogen) was used for cDNA synthesis, and Pyrobest DNA polymerase (Takara Bio) for 25-30 cycles of cDNA amplification. Reverse transcription-PCRs were performed using the following primer sets (Table 2 ): SA1rt and SA1fw+SA1rv for Frag-1 (nt 1-2553), SA2rt and SA2fw+SA2rv for Frag-2 (nt 1800-5950), SA3rt and SA3fw+SA3rv for Frag-3 (nt 5500-9401) and SA4rt and SA4fw+SA4rv for Frag-4 (nt 9200-10 977). Each of the four PCR products was excised from an agarose gel and purified using a QIAquick Gel Extraction Kit (Qiagen). The purified cDNA amplicons were directly sequenced on both strands with internal primers located~400 bases apart.
The 5¢-and 3¢-terminal nt sequences of JEV genomic RNA were analysed by self-ligation of a linear viral RNA and subsequent reverse transcription-PCR across the ligation site of the circularized RNA (Yun et al., 2003b) . Viral genomic RNA was treated with the capremoving enzyme tobacco acid pyrophosphatase (TAP, Epicentre) in a 20 µl reaction mixture containing 10 µl viral RNA, 10 U TAP and the buffer supplied by the manufacturer. After incubation at 37 C for 1 h, the TAP-treated RNA was phenol-extracted, ethanol-precipitated and resuspended with 20 µl of dH 2 O. Half of the decapped RNA was selfligated in a 20 µl reaction mixture with T4 RNA ligase (New England Biolabs). A quarter of the self-ligated RNA was used for reverse transcription-PCR with a set of primers, SACCrt and SACCfw +SACCrv (Table 2) . Subsequently, the 1226 bp SacI-NcoI fragment of the resulting amplicons was ligated with the 2741 bp SacI-NcoI fragment of pRS2 vector. The selected individual clones with the insert were then subjected to DNA sequencing.
Sequence analysis and RNA pseudoknot structure prediction.
The complete genome sequence of JEV SA 14 was compiled using SeqMan in the Lasergene software package (DNASTAR) and deposited in the GenBank sequence database with the accession no. KU323483. Multiple and pairwise sequence alignments were performed using MegAlign (DNASTAR). RNA pseudoknot structures were predicted using the IPknot program (Sato et al., 2011) , accessible via the Rtips web server at http://rtips.dna.bio.keio.ac.jp/ (Kato et al., 2012) .
